Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases

The goal of this clinical trial is to study the efficiency and safety of using combinations of antihyperlipidemic agents with a single drug to treat cardiovascular diseases.

The main questions it aims to answer are:

* Which approach is more effective rosuvastatin monotherapy or rosuvastatin ezetimibe combination antihyperlipidemic for patients with cardiovascular diseases (CVDs)? * What medical problems do participants could when taking antihyperlipidemic drugs? Researchers will compare rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg to see the effectiveness and safety of these drugs in patients with CVDs.

Participants will:

* Patients will randomize to either rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg. * Patients will be followed up to 12 weeks after starting treatment. * All the patients will be subjected to: Full sheet taking, including detailed history and diagnosis of the case, Baseline Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) tests& after 24 weeks of treatment, Lipid Profile, creatine kinase (CK) test, Creatine kinase-MB (CK-MB) test.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Diseases (CVD) Cardiovascular Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Beni-Suef University Hospital

Banī Suwayf, Beni Suweif Governorate, 62521, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults above 18 years, Dyslipidemic patients

Exclusion criteria

Young people under 18 years old pregnant women lactating women Children Hypersensitivity Renal failure

Treatment and study plan

rosuvastatin drug

Drug

Patients randomized to receive rosuvastatin 20 mg

Patients received rosuvastatin ezetimibe10/10mg

Combination Product

Patients received rosuvastatin ezetimibe10/10mg

Primary outcomes

Creatine Kinase

Time frame: at baseline and after 12 weeks

Sponsors and collaborators

Lead sponsor

Beni-Suef University

Other

Registry information

Official study title

The Efficiency and Safety of Single Drug Versus Combinations of Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Dec 31, 2025
Registry last updated: Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed